MapLight Therapeutics, Inc. Common Stock (MPLT) is a publicly traded the market company. As of May 21, 2026, MPLT trades at $27.81 with a market cap of $1.20B and a P/E ratio of -1.47. MPLT moved +2.99% today. Year to date, MPLT is +61.50%; over the trailing twelve months it is flat. Its 52-week range spans $12.24 to $33.28. Analyst consensus is strong buy with an average price target of $38.26. Rallies surfaces MPLT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MapLight Completes 307-Patient Schizophrenia and 161-Patient Autism Trials; Q1 Cash $395M: MapLight completed enrollment in its 307-patient Phase 2 ZEPHYR schizophrenia trial and 161-patient Phase 2 IRIS autism spectrum disorder study, with topline results due by mid-August 2026. The Phase 2 VISTA Alzheimer’s disease psychosis trial continues with ~300 participants, and the company ended Q1 with $395.2M cash funding operations through 2027.
| Metric | Value |
|---|---|
| Price | $27.81 |
| Market Cap | $1.20B |
| P/E Ratio | -1.47 |
| EPS | $-18.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.28 |
| 52-Week Low | $12.24 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-161.15M |
| Gross Margin | 0.00% |
6 analysts cover MPLT: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.26.